Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

It is the biggest shake-up of obesity treatment in NHS history, it has been claimed. From later this month, GPs will be able ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Among those who adhered to treatment, the high-dose group achieved an average weight loss of 20.7% ... health benefits already established with Wegovy, including cardiovascular risk reduction ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo ... to take the highest dose of the drugs they were able ...

The organization is providing trainers with information and education for how to coach clients taking the weight-loss ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

The medication initially helped get his type 2 diabetes into remission, and enjoy active social excursions that he couldn't ...